DDInter1642 DDInter1485
Sargramostim is a human recombinant granulocyte macrophage colony-stimulating factor (GM-CSF) expressed in yeast. It is a glycoprotein that is 127 residues. Substitution of Leu23 leads to a difference from native protein.
Polatuzumab vedotin is a CD79b-directed antibody-drug conjugate that delivers monomethyl auristatin E (MMAE), an anti-mitotic agent, to cancer cells. The drug consists of three components - a humanized immunoglobulin G1 (IgG1) monoclonal antibody specific for human CD79b (polatuzumab), MMAE, and protease-cleavable linker called maleimidocaproyl-valine-citrulline-p-aminobenzyloxycarbonyl (mc-vc-PAB) that covalently attaches MMAE to polatuzumab. Polatuzumab vedotin was granted accelerated FDA approval on June 10, 2019 and was approved by Health Canada on July 9, 2020.
Polatuzumab vedotin {u} may cause a minor interaction that can limit clinical effects when taken with {v} Enzalutamide
Polatuzumab vedotin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Simvastatin
Polatuzumab vedotin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Secnidazole
Polatuzumab vedotin {u} may lead to a major life threatening interaction when taken with {v} Clarithromycin
Polatuzumab vedotin {u} may lead to a major life threatening interaction when taken with {v} Upadacitinib
Polatuzumab vedotin may cause a minor interaction that can limit clinical effects when taken with Enzalutamide
Polatuzumab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Simvastatin
Polatuzumab vedotin may cause a moderate interaction that could exacerbate diseases when taken with Secnidazole
Polatuzumab vedotin may lead to a major life threatening interaction when taken with Clarithromycin
Polatuzumab vedotin may lead to a major life threatening interaction when taken with Upadacitinib